Skip to main content

Alliance Equity Research

Research

Browse AER initiation reports, research updates, earnings analysis, flash notes, and company commentary.

4 reports

HLP003 Achieves Statistically Significant Phase 3 Efficacy with Sustained Benefits Through Week 12, Supporting Higher Development Success Probability

HLP003 beat placebo by 7.6 points on the MADRS depression scale at Week 6 and by 7.0 points at Week 12. AER raises its illustrative valuation to $20.00 per share and examines three treatment-related serious adverse events, confirmatory trial timing, and quarterly cash use.

Research UpdateIndependent Research
Healthcare · 13 pages